Maravai LifeSciences (NASDAQ:MRVI) Upgraded by Wall Street Zen to “Hold” Rating

Maravai LifeSciences (NASDAQ:MRVI) was upgraded by equities research analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a report released on Saturday.

Separately, Wells Fargo & Company increased their target price on Maravai LifeSciences from $4.00 to $4.50 and gave the company an “overweight” rating in a research note on Monday, December 15th. Four analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, Maravai LifeSciences currently has a consensus rating of “Hold” and an average target price of $5.25.

Maravai LifeSciences Stock Performance

Shares of MRVI opened at $3.56 on Friday. Maravai LifeSciences has a 52-week low of $1.66 and a 52-week high of $4.11. The company has a quick ratio of 4.56, a current ratio of 5.29 and a debt-to-equity ratio of 0.74. The firm has a market cap of $910.33 million, a price-to-earnings ratio of -3.96 and a beta of 0.39. The business’s 50 day moving average is $3.44 and its two-hundred day moving average is $3.20.

Maravai LifeSciences (NASDAQ:MRVI) last announced its quarterly earnings results on Wednesday, February 25th. The company reported ($0.04) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.07) by $0.03. Maravai LifeSciences had a negative net margin of 70.40% and a negative return on equity of 21.55%. The company had revenue of $49.87 million during the quarter, compared to the consensus estimate of $49.06 million. Analysts forecast that Maravai LifeSciences will post -0.24 EPS for the current fiscal year.

Insider Transactions at Maravai LifeSciences

In related news, Director Gregory T. Lucier purchased 51,472 shares of Maravai LifeSciences stock in a transaction on Friday, December 5th. The shares were purchased at an average price of $3.70 per share, for a total transaction of $190,446.40. Following the transaction, the director owned 106,595 shares of the company’s stock, valued at approximately $394,401.50. This represents a 93.38% increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available at this hyperlink. 2.11% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Maravai LifeSciences

Several institutional investors have recently modified their holdings of MRVI. Barclays PLC boosted its holdings in Maravai LifeSciences by 3.0% in the 4th quarter. Barclays PLC now owns 172,281 shares of the company’s stock worth $560,000 after buying an additional 5,057 shares during the period. The Manufacturers Life Insurance Company boosted its holdings in shares of Maravai LifeSciences by 12.5% in the second quarter. The Manufacturers Life Insurance Company now owns 46,528 shares of the company’s stock worth $112,000 after acquiring an additional 5,160 shares during the period. Performa Ltd US LLC lifted its holdings in Maravai LifeSciences by 33.3% during the 2nd quarter. Performa Ltd US LLC now owns 22,990 shares of the company’s stock worth $55,000 after purchasing an additional 5,740 shares in the last quarter. Epacria Capital Partners LLC boosted its stake in Maravai LifeSciences by 6.8% in the 3rd quarter. Epacria Capital Partners LLC now owns 100,078 shares of the company’s stock worth $287,000 after purchasing an additional 6,384 shares during the period. Finally, Ethic Inc. grew its holdings in Maravai LifeSciences by 62.8% during the 3rd quarter. Ethic Inc. now owns 16,951 shares of the company’s stock valued at $49,000 after buying an additional 6,540 shares in the last quarter. 50.25% of the stock is owned by institutional investors.

Maravai LifeSciences Company Profile

Maravai LifeSciences Holdings, Inc (NASDAQ: MRVI) is a life sciences company specializing in the development and supply of critical reagents and services for the development and manufacture of biologic therapies. The company’s offerings support a range of applications in genomics, molecular diagnostics, vaccine development and next-generation sequencing. Maravai’s platforms address key challenges in nucleic acid production, protein detection, epigenetic analysis and reagent quality across the biopharmaceutical industry.

Through its product portfolio, which includes proprietary mRNA capping reagents, lipid nanoparticle delivery systems, synthetic oligonucleotides and high-precision assay kits, Maravai enables customers to accelerate research and streamline manufacturing workflows.